8月6日

E62 #StartupStory “AI-Driven Antibody Design: A Journey from Academia to Industry” with Rahmad Akbar Senior data scientist at Novo Nordisk

In this episode of Life Science Talent Talks, host Nehar Mortuza sits down with Rahmad Akbar, Senior Data Scientist in Antibody Design at Novo Nordisk. Rahmad shares his remarkable journey from his roots in Indonesia to his pivotal role at the forefront of machine learning-driven protein engineering. Together, they explore how AI is revolutionising antibody design — from the technical advances and current challenges to the growing role of generative models in creating next-generation therapeutics. Rahmad offers insights into how these technologies are accelerating drug discovery, improving patient outcomes, and shaping the future of healthcare. He also speaks candidly about his transition from academia to industry, the personal motivations that fuel his work, and why collaboration and innovation are more essential than ever in the life sciences. Whether you're passionate about biotech, data science, or career development, this episode is packed with valuable perspectives you won't want to miss. Timestamp and Show notes: 00:38 Meet Our Special Guest: Rahmad Akbar 02:19 Rahmad's Journey: From Indonesia to Novo Nordisk 03:35 The Role of Coding in Biotechnology 04:45 Antibody Design: Challenges and Innovations 06:48 Generative AI in Drug Design 10:04 Future Trends and Democratizing AI 19:00 Personal Motivations and Career Reflections 24:31 Transitioning from Academia to Industry 29:47 Final Thoughts and Takeaways Ideas for future podcast guests or themes? 💡 We want to co-create this podcast with you. We'd therefore love to hear your suggestions for future podcast guests or themes. Join Our Life Science Talent Ecosystem We want to build a community to inspire life science professionals and leaders through talent talks and organised events. Share knowledge across the life science community through personal stories of their journey. We encourage you to take part in shaping this community by sharing your feedback, questions, or ideas. This you can do through our LinkedIn⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠community page⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠. Warm Regards from your podcast hosts: ⁠⁠⁠⁠⁠⁠⁠⁠⁠Nehar Mortuza⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ and⁠⁠⁠ ⁠⁠⁠Søren Spanner Bach

32 分鐘

8月6日

E61 #StartupStory "Mmimetika's science based dietary supplement that mimics the body’s natural response to exercise and fasting" with Thomas Poulsen & Mogens Johannsen

In this episode, we take you inside the story of Mmimetika, a biotech venture co-founded by researchers Mogens Johannsen and Thomas Poulsen. What began as a bold university lab project has grown into a breakthrough company developing a compound that mimics some of the key health benefits of exercise and fasting. By combining ketones and lactate in a single, novel molecule, Mmimetika's lactate | ketone non-medicinal supplement provides promising support for metabolic control and longevity. We dive into their journey from academic discovery to commercial reality — securing patents, scaling production, attracting investors, and building a business team around their scientific vision. Now on the cusp of regulatory approval, Mmimetika is actively searching for a dynamic CEO to lead the charge into market launch and long-term growth. Whether you're curious about biotech entrepreneurship, metabolic health innovations, or how groundbreaking research turns into real-world solutions, this is a story you won’t want to miss. Shownotes and Timestamps [00:00:00] Company Introduction [00:01:12] Mimicking Exercise and Fasting [00:04:08] Current Status and Journey [00:05:54] Product Superiority and Development [00:08:13] Competition and IP [00:10:18] Funding and Investor Relations [00:11:17] Technical Aspects of the Product [00:13:00] Clinical Evidence and Scientific Approach [00:14:22] Non-Medical Claims [00:15:29] Market Focus and Positioning [00:17:58] Roadmap and Milestones [00:21:22] Organizational Structure and Key Risks [00:23:00] CEO Transition and Future Roles [00:25:04] Company Culture and CEO Profile [00:27:26] Soft Skills and Ideal Timing for CEO [00:29:42] How Listeners Can Support Ideas for future podcast guests or themes? 💡 We want to co-create this podcast with you. We'd therefore love to hear your suggestions for future podcast guests or themes. Feel free to share in a private message or leave a comment below 🙏🏼 (It's also ok to invite yourself 😉) Join Our Life Science Talent Ecosystem We want to build a community to inspire life science professionals and leaders through talent talks and organized events. Share knowledge across the life science community through personal stories of their journey. We encourage you to take part in shaping this community by sharing your feedback, questions, or ideas. This you can do through our LinkedIn⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠community page⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠. Warm Regards from your podcast hosts: ⁠⁠⁠⁠⁠⁠⁠⁠⁠Nehar Mortuza⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ and⁠⁠⁠ ⁠⁠⁠Søren Spanner Bach

31 分鐘

7月4日

E60 #StartupStory "The New Frontier: miRNA Therapies Changing Lives" with Janine Erler & Lluís Riera Ponsati

In this episode, we sit down with Janine Erler, CEO, and Lluís Riera Ponsati, Program Lead at NEUmiRNA Therapeutics to discuss their groundbreaking work in developing disease-modifying RNA therapies for neurological disorders. From their startup journey to the intricate science behind their therapies, the conversation spans key milestones, technology challenges, and the unique patient-focused culture at Neumirna. Janine and Lluís share insights on their successful fundraising, the impact of their microRNA-based approach, and the practical aspects of going from academic research to clinical applications. They also discuss the organizational dynamics, collaborations, and future aspirations of the company, making this a compelling listen for any life sciences professional interested in the transformative potential of RNA therapies. Show notes & Timestamp 00:43 Introducing Neumirna Therapeutics 02:10 Founding Story of Neumirna 03:29 Key Milestones and Team Growth 06:50 Challenges and Collaborations 15:23 Technology Behind Neumirna's RNA Therapies 23:19 Focus on Neurological Diseases 24:57 Exploring the Potential of ASO Technology 25:26 The Future of RNA Therapies 27:44 Navigating Regulatory Challenges 28:37 Team and Culture at Neumirna 35:23 Hiring and Onboarding at Neumirna 37:36 Proud Moments and Achievements 43:02 Immediate Priorities and Challenges 44:43 Connecting with the Community 45:51 Conclusion and Final Thoughts Ideas for future podcast guests or themes? 💡 We want to co-create this podcast with you. We'd therefore love to hear your suggestions for future podcast guests or themes. Feel free to share in a private message or leave a comment below 🙏🏼 (It's also ok to invite yourself 😉) Join Our Life Science Talent Ecosystem We want to build a community to inspire life science professionals and leaders through talent talks and organized events. Share knowledge across the life science community through personal stories of their journey. We encourage you to take part in shaping this community by sharing your feedback, questions, or ideas. This you can do through our LinkedIn⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠community page⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠. Warm Regards from your podcast hosts: ⁠⁠⁠⁠⁠⁠⁠⁠⁠Nehar Mortuza⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ and⁠⁠⁠ ⁠⁠⁠Søren Spanner Bach

45 分鐘

6月22日

E59 #StartupStory "Enabling Fungi Innovation to Solve Humanity’s Largest Challenges" with Susanne Gløersen

In this episode, Susanne Gløersen, founder of The Future of Fungi Award and Fungi Investment Collective, discusses her mission to build a global ecosystem fueled by fungi innovation. The conversation covers the multifaceted applications of fungi, from food and materials to packaging and environmental remediation. Susanne shares the origins of her passion for fungi, the purpose and success of the Future Fungi Award, and the criteria for selecting award winners and investment opportunities. She emphasizes the role of fungi in addressing pressing environmental issues and the importance of collaboration and community in advancing fungi innovation. Additionally, Susanne dives into the workings of the Fungi Investment Collective, highlighting how it supports pioneering scientists and startups with funding and resources. Essential for anyone interested in sustainable innovation, this episode unveils the transformative potential of fungi and how it can drive us towards a more balanced and nature-cooperative economy. Shownotes and Timestamps 00:55 Introduction and Overview of Fungi Innovation 01:55 Susanne's Background and Journey into Fungi 04:48 Mission and Vision for Fungi Innovation 06:38 The Future Fungi Award 08:07 Highlighting Award Winners and Their Innovations 15:06 Support and Collaboration Opportunities 19:22 Introduction to the Fungi Investment Collective 24:46 Building a Network of Science Venture Partners 25:30 Investment Priorities and Criteria 26:54 Funding Ranges and Case Dependency 27:54 Connecting with the Fungi Investment Collective 28:55 Opportunities for Aspiring Venture Partners 32:33 Proud Accomplishments and Network Effects 36:27 Challenges and Learnings as a First-Time Entrepreneur 41:12 Future of Fungi Innovation and Exciting Startups 46:33 Conclusion and Call to Join the Movement Resources Mentioned: Awards, Collectives, and Initiatives - Fungi Investment Collective - Venture Builder Pilot Program (for top scientists) - The Mycelium Network (community concept) Podcasts & Media - The Future is Fungi Podcast Notable Startups & Projects - Jens Laurids Sørensen (battery out of fungi) - Nova Biome (textile waste to bioactive compounds for cosmetics, in L'Oreal's accelerator) - Line Kloster Pedersen, Visibuilt (Danish startup making mycelium binder for asphalt production) - William Newell, Electromicrobial CO2 fixation project (Imperial College of London) - Nomy (Norwegian Mycelium, feed for aquaculture) - Michael Lever (German company, surfactants from fungi) Conferences & Events - ChangeNow (largest accessibility conference) - IMC12 (International Mycology Congress) - Brilliant Minds (an event where Obama and Malala have spoken) Corporates & Partners - L'Oreal (accelerator) - Novo Holdings (jury pre-screening) - SEB (Green Tech VC, large Nordic Bank) Book Recommendations -Entangled Life by Merlin Sheldrake Other - LinkedIn (The Fungi Investment Collective) - Fungi Investment Collective website/contact form - Email: Suzanne@fungiinvestmentcollective.com Ideas for future podcast guests or themes? 💡 We want to co-create this podcast with you. We'd therefore love to hear your suggestions for future podcast guests or themes. Feel free to share in a private message or leave a comment below 🙏🏼 (It's also ok to invite yourself 😉) Join Our Life Science Talent Ecosystem We want to build a community to inspire life science professionals and leaders through talent talks and organized events. Share knowledge across the life science community through personal stories of their journey. We encourage you to take part in shaping this community by sharing your feedback, questions, or ideas. This you can do through our LinkedIn⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠community page⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠. Warm Regards from your podcast hosts: ⁠⁠⁠⁠⁠⁠⁠⁠ Nehar Mortuza⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ and⁠⁠⁠ ⁠⁠⁠Søren Spanner Bach

40 分鐘

5月26日

E58 #Leadership “Life Science Talent Talks: Mikkel Skovborg on Innovation, Talent & the Future of Biotech”

In this episode of Life Science Talent Talks, Nehar Mortuza looks into the dynamic world of life sciences with special guest Mikkel Skovborg, Vice President at the Novo Nordisk Foundation. Mikkel shares his journey from academia to industry and discusses the foundation’s mission to foster innovation, entrepreneurship, and scientific research. He highlights key initiatives like the Bio Innovation Institute (BII) and public-private partnerships that aim to enhance the life science ecosystem in Denmark and beyond. The conversation covers the impact of regulatory challenges, the promise of emerging technologies such as quantum computing and gene cell therapy, and the importance of global talent and collaborations. Mikkel also provides insights on the evolving landscape of life sciences, offering advice to aspiring professionals and reflecting on the lessons learned throughout his career. Timestamps: 00:45 | Introducing Our Guest – Mikkel Skovborg 01:36 | Career Journey & Influences – From Academia to Industry 04:15 | The Mission & Impact of the Novo Nordisk Foundation 07:22 | Challenges & Opportunities in the Life Science Sector 14:03 | Denmark’s Role as a Hub for Startups & Talent 16:19 | Personal Insights & Reflections from Mikkel Skovborg 19:20 | Conclusion & Key Takeaways Ideas for future podcast guests or themes? 💡 We want to co-create this podcast with you. We'd therefore love to hear your suggestions for future podcast guests or themes. Feel free to share in a private message or leave a comment below 🙏🏼 (It's also ok to invite yourself 😉) Join Our Life Science Talent Ecosystem We want to build a community to inspire life science professionals and leaders through talent talks and organized events. Share knowledge across the life science community through personal stories of their journey. We encourage you to take part in shaping this community by sharing your feedback, questions, or ideas. This you can do through our LinkedIn⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠community page⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠. Warm Regards from your podcast hosts: ⁠⁠⁠⁠⁠⁠⁠⁠⁠Nehar Mortuza⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ and⁠⁠⁠ ⁠⁠⁠Søren Spanner Bach

20 分鐘

5月16日

E57 #StartupStory "Succession planning: Passing on the CEO baton in Algiecel" with Susanne Palsten Buchardt & Henrik Busch-Larsen

Guests: Susanne Palsten Buchardt (Incoming CEO) & Henrik Busch‑Larsen (Founder, former CEO at Algiecel) Episode in a Tweet When a founder steps aside, how do you keep the vision alive? Hear how Algiecel is turning a CEO hand‑over into rocket fuel for growth — while scaling microalgae tech that captures CO₂ and feeds the world. What You’ll Learn How Algiecel’s photo‑bioreactor technology converts industrial CO₂ into high‑value microalgae ingredients. The behind‑the‑scenes playbook for planning a smooth CEO succession. Why trust, transparent communication, and role clarity made the hand‑over a win‑win. Susanne’s journey from strategy consultant to CCO to CEO—and Henrik’s new focus on partnerships & investment. Actionable advice for founders preparing their own succession road‑map. 00:00 Intro – Welcome & episode set‑up 02:04 Algiecel’s Mission & Tech – Microalgae, CO₂ utilisation, and photo‑bioreactors 04:45 Origin Story – Henrik’s eco‑vision and the company’s early pivots 09:08 Why Succession & Why Now? – Spotting the right moment for change 12:56 From CCO to CEO – Susanne’s growth path and leadership style 16:05 Building the Dream Team – Diversity, healthy debate, and shared values 21:10 Board & Investor Alignment – Governance during leadership change 22:40 Redefining Roles – Henrik’s shift to partnerships & thought leadership 25:02 Stakeholder Communications – Keeping customers & partners in the loop 30:12 Founders’ Advice – Mentorship, self‑awareness, and planning ahead 36:47 Future Road‑map – Scaling tech, funding, and global impact 38:50 Lightning Round & Wrap‑up – Quick takes and final thoughts Resource Mentioned: Unibio – Single‑cell protein pioneers BioInnovation Institute (BII) – Life‑science venture lab Ideas for future podcast guests or themes? 💡 We want to co-create this podcast with you. We'd therefore love to hear your suggestions for future podcast guests or themes. Feel free to share in a private message or leave a comment below 🙏🏼 (It's also ok to invite yourself 😉) Join Our Life Science Talent Ecosystem We want to build a community to inspire life science professionals and leaders through talent talks and organized events. Share knowledge across the life science community through personal stories of their journey. We encourage you to take part in shaping this community by sharing your feedback, questions, or ideas. This you can do through our LinkedIn⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠community page⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠.Warm Regards from your podcast hosts: ⁠⁠⁠⁠⁠⁠⁠⁠⁠Nehar Mortuza⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ and⁠⁠⁠ ⁠⁠⁠Søren Spanner Bach

41 分鐘

5月14日

E56 (Full) #StartupStory “Building a Trust-Based Culture in High-Pressure Biotech Startups” Insights from Thomas Kirkegaard Jensen CEO of Amplify Therapeutics

In this episode of Life Science Talent Talks, Thomas Kirkegaard Jensen, CEO of Amplify Therapeutics and a seasoned entrepreneur in the life science startup world, joins Søren for an in-depth conversation about building healthy company culture in high-pressure environments. Drawing on over 15 years of experience—including his pivotal role at Orphazyme, where he contributed to the development and FDA approval of a groundbreaking rare disease treatment (now part of Zevra Therapeutics through acquisition) The discussion explores how to foster trust-based, high-performance cultures, with a focus on psychological safety, clear communication, competence mapping, and managing the organizational challenges that come with growth. Thomas reflects on his leadership style, the importance of understanding personal strengths and blind spots, and the tools and systems he uses to shape team culture intentionally. Thomas shares practical insights on when to begin deliberately cultivating culture, how Amplify Therapeutics approaches team dynamics, and the key lessons he’s learned from leading in both startup and scale-up phases. The conversation also touches on milestones in team development and R&D, and Thomas’s vision for the company’s future. This episode is especially relevant for startup leaders and life science professionals interested in entrepreneurship, innovation, and building strong, sustainable teams in complex, high-stakes environments. Timestamp and Shownotes: 00:43 – Thomas’s Journey in Biotech 02:04 – Deep Dive into Amplify Therapeutics 06:53 – The Birth of Amplify Therapeutics 16:40 – Building a Healthy Startup Culture 34:23 – Specialization and Responsibility Shifts 35:33 – Leadership and Organizational Growth 38:05 – Competence Mapping and Skills Assessment 39:33 – Trust and Communication in Teams 45:22 – Balancing Fast Decisions with Thoughtfulness 52:28 – Reflections on Achievements and Culture 55:18 – Advice for First-Time CEOs 56:43 – Future Challenges and Opportunities 58:15 – Support and Career Opportunities 01:02:39 – The Reality of Working in Biotech Ideas for future podcast guests or themes? 💡 We want to co-create this podcast with you. We'd therefore love to hear your suggestions for future podcast guests or themes. Feel free to share in a private message or leave a comment below 🙏🏼 (It's also ok to invite yourself 😉) Join Our Life Science Talent Ecosystem We want to build a community to inspire life science professionals and leaders through talent talks and organized events. Share knowledge across the life science community through personal stories of their journey. We encourage you to take part in shaping this community by sharing your feedback, questions, or ideas. This you can do through our LinkedIn⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠community page⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠. Warm Regards from your podcast hosts: ⁠⁠⁠⁠⁠⁠⁠⁠⁠Nehar Mortuza⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ and⁠⁠⁠ ⁠⁠⁠Søren Spanner Bach

1 小時 6 分鐘

5月14日

E56 (Teaser) #StartupStory “Amplify Therapeutics: A Scalable Approach to High-Impact Biotech” with Thomas Kirkegaard Jensen CEO of Amplify Therapeutics

15 min teaser episode. Listen to the full episode in EP56 (Full). Today we're diving into a biotech story that should be on every venture capitalist’s radar: Amplify Therapeutics. This is a company that’s shaking up drug development for neurodegenerative diseases—think ALS, Parkinson’s, frontotemporal dementia—not by throwing money at the problem, but by building smarter, faster, and more efficiently. Founded by Thomas Kirkegaard Jensen—yes, the same scientific mind behind the legacy of Orphazyme—Amplify is zeroing in on lysosomal function and proteostasis, two mechanisms that hold huge promise across multiple disease areas. But here’s the kicker: they’re doing it lean. They’ve built a capital-efficient model, using validated targets and real-world biomarkers to reduce risk and speed up timelines. This isn’t a moonshot—it’s a well-designed, data-driven platform with serious scalability. And with their first program heading into the clinic, Amplify is already primed for partnerships, licensing deals, and smart funding. Add a leadership team with deep regulatory experience and a proven track record of exits, and you’ve got a company that’s not just ready for the next phase—it’s ready to lead. For VCs looking for high-impact biotech with serious upside, this is one worth watching. Stay tuned—Amplify is just getting started. Timestamp and Shownotes: 00:00:41 – Thomas shares his entry into biotech via Orphazyme 00:02:00 – Thomas emphasizes the importance of trust-based and healthy team culture for high-performance in biotech environments. 00:02:09 – Thomas explains Amplify’s mission: to develop medicines for genetically defined neurodegenerative diseases by targeting lysosomal biology. 00:03:00 – Discussion on whether Amplify is a platform-based company or asset-driven. Thomas describes their diversified small-molecule approach grounded in deep lysosomal expertise. 00:04:00 – Thomas shares how he reacquired assets from Zevra after Orphazyme's dissolution and spun them into a new company, Amplify Therapeutics. 00:06:00 – Licensing + Foundation of Amplify 00:06:33 – Thomas outlines how he secured a startup grant from BioInnovation Institute (BII) in Copenhagen while finalizing the licensing deal. 00:07:51 – Early Team Building 00:08:33 – Thomas discusses balancing speed, flexibility, and internal know-how through selective in-house work. 00:09:41 – Thomas explains their hybrid approach: outsourcing standard assays, while keeping complex, specialized biology assays in-house for better agility and knowledge retention. 00:11:12 – Current Pipeline Overview Amplify’s portfolio includes three projects: Lead program with multiple chemistries Oxford University collaboration Potential Danish Cancer Society program 00:12:14 – Amplify is preparing for a fundraising round to scale operations and advance pipeline development Ideas for future podcast guests or themes? 💡 We want to co-create this podcast with you. We'd therefore love to hear your suggestions for future podcast guests or themes. Feel free to share in a private message or leave a comment below 🙏🏼 (It's also ok to invite yourself 😉) Join Our Life Science Talent Ecosystem We want to build a community to inspire life science professionals and leaders through talent talks and organized events. Share knowledge across the life science community through personal stories of their journey. We encourage you to take part in shaping this community by sharing your feedback, questions, or ideas. This you can do through our LinkedIn⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠community page⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠. Warm Regards from your podcast hosts: ⁠⁠⁠⁠⁠⁠⁠⁠⁠Nehar Mortuza⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ and⁠⁠⁠ ⁠⁠⁠Søren Spanner Bach

14 分鐘

Life Science Talent Talks

E62 #StartupStory “AI-Driven Antibody Design: A Journey from Academia to Industry” with Rahmad Akbar Senior data scientist at Novo Nordisk

E61 #StartupStory "Mmimetika's science based dietary supplement that mimics the body’s natural response to exercise and fasting" with Thomas Poulsen & Mogens Johannsen

E60 #StartupStory "The New Frontier: miRNA Therapies Changing Lives" with Janine Erler & Lluís Riera Ponsati

E59 #StartupStory "Enabling Fungi Innovation to Solve Humanity’s Largest Challenges" with Susanne Gløersen

E58 #Leadership “Life Science Talent Talks: Mikkel Skovborg on Innovation, Talent & the Future of Biotech”

E57 #StartupStory "Succession planning: Passing on the CEO baton in Algiecel" with Susanne Palsten Buchardt & Henrik Busch-Larsen

E56 (Full) #StartupStory “Building a Trust-Based Culture in High-Pressure Biotech Startups” Insights from Thomas Kirkegaard Jensen CEO of Amplify Therapeutics

E56 (Teaser) #StartupStory “Amplify Therapeutics: A Scalable Approach to High-Impact Biotech” with Thomas Kirkegaard Jensen CEO of Amplify Therapeutics

簡介

資訊

你可能也會喜歡

Life Science Talent Talks

集數

E62 #StartupStory “AI-Driven Antibody Design: A Journey from Academia to Industry” with Rahmad Akbar Senior data scientist at Novo Nordisk

E61 #StartupStory "Mmimetika's science based dietary supplement that mimics the body’s natural response to exercise and fasting" with Thomas Poulsen & Mogens Johannsen

E60 #StartupStory "The New Frontier: miRNA Therapies Changing Lives" with Janine Erler & Lluís Riera Ponsati

E59 #StartupStory "Enabling Fungi Innovation to Solve Humanity’s Largest Challenges" with Susanne Gløersen

E58 #Leadership “Life Science Talent Talks: Mikkel Skovborg on Innovation, Talent & the Future of Biotech”

E57 #StartupStory "Succession planning: Passing on the CEO baton in Algiecel" with Susanne Palsten Buchardt & Henrik Busch-Larsen

E56 (Full) #StartupStory “Building a Trust-Based Culture in High-Pressure Biotech Startups” Insights from Thomas Kirkegaard Jensen CEO of Amplify Therapeutics

E56 (Teaser) #StartupStory “Amplify Therapeutics: A Scalable Approach to High-Impact Biotech” with Thomas Kirkegaard Jensen CEO of Amplify Therapeutics

簡介

資訊

你可能也會喜歡